Publications found:
3,191
Sort by:
NOVARTIS
US$ 90.00
For the fourth quarter 2011, in line with our expectations, NVS Sales grew 5%, and core EPS advanced 8%. NVS also announced full year dividend for 2011 at CHF 2.25, which translates into a meager 2%, increase, which we think is a dampener. The 2012 guidance as well was lackluster as NVS expects net sales in ...
January 2012
2 pages
Yoghurt and Sour Milk Drinks in Switzerland
US$ 990.00
... showed a beautiful woman eating the yoghurt with the slogan, beauty to be enjoyed. Euromonitor International's Yoghurt and Sour Milk Drinks in Switzerland report offers a comprehensive guide to the ... , Condensed/Evaporated Milk, Cream, Flavoured Milk Drinks, Flavoured Powder Milk Drinks, Fromage Frais and Quark, Milk, Powder Milk, Processed Cheese, Sour Milk Drinks, Soy Beverages, Unprocessed Cheese, Yoghurt. Data ...
December 2011
65 pages
NOVARTIS - Tekturna: ALTITUDE study in high risk hypertensive patients TERMINATED
US$ 90.00
... the termination of large PhIII study (ALTITUDE) due to higher rate of adverse events and no benefits observed for patients taking Tekturna in addition to ACE ... inhibitors. Post this announcement, NVS will cease promotion of Tekturna/Tekturna products in combination with ACE inhibitors/ARB inhibitors. The event ...
December 2011
1 pages
